EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study

Maria Pokorska-Śpiewak iD, Ewa Talarek, Małgorzata Aniszewska, Magdalena Pluta, Anna Dobrzeniecka, Magdalena Marczyńska, Giuseppe Indolfi iD

Liver International · 2023-09 · 43 (9) · 1871-1878

DOI: 10.1111/liv.15637 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Liver International, online erschienen am 08.06.2023. Verfasst von Maria Pokorska-Śpiewak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Sofosbuvir, Hepatitis C, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The aim of this non‐commercial, open‐label, real‐life, non‐randomized clinical trial was to analyse the efficacy and safety of a pangenotypic regimen sofosbuvir/velpatasvir (SOF/VEL) in patients aged 6–18 years with chronic hepatitis C virus (HCV) infection. Methods Fifty patients qualified for the 12‐week treatment were divided into two weight groups: 15 children weighting between 17 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirHepatitis C, ChronicChildHumansAntiviral AgentsTreatment OutcomeHeterocyclic Compounds, 4 or More RingsHepacivirusGenotypeSustained Virologic ResponseBenzimidazolesBenzopyransCarbamates

Stichwörter der Autor:innen

childrendirect acting antiviralshepatitis C virussofosbuvir/velpatasvir

Substanzen

SofosbuvirAntiviral AgentsHeterocyclic Compounds, 4 or More RingsvelpatasvirBenzimidazolesBenzopyransCarbamates

Autor:innen und Institutionen

  • Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
  • Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland.
  • Department of Neurofarba, Meyer Children's University of Florence, Florence, Italy.

ORCID-Profile: Maria Pokorska-Śpiewak, Giuseppe Indolfi

Zitieren

APA

Pokorska-Śpiewak, M., Talarek, E., Aniszewska, M., Pluta, M., Dobrzeniecka, A., Marczyńska, M., & Indolfi, G. (2023). Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study. Liver International, 43(9), 1871-1878. https://doi.org/10.1111/liv.15637

Vancouver

Pokorska-Śpiewak M, Talarek E, Aniszewska M, Pluta M, Dobrzeniecka A, Marczyńska M, et al. Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study. Liver International. 2023;43(9):1871-1878. doi:10.1111/liv.15637

BibTeX
@article{Pokorskapiewak2023,
  author = {Pokorska-Śpiewak, Maria and Talarek, Ewa and Aniszewska, Małgorzata and Pluta, Magdalena and Dobrzeniecka, Anna and Marczyńska, Magdalena and Indolfi, Giuseppe},
  title = {Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study},
  journal = {Liver International},
  year = {2023},
  volume = {43},
  number = {9},
  pages = {1871--1878},
  doi = {10.1111/liv.15637}
}
Kostenlos starten →